Monday, 31 August 2026European Markets

OREGE Stock Went Down By Over 9% So Far Today

Loading stream...

orege, a french manufacturer of municipal and industrial sludge treatments, experienced an alarming 9.81% fall to eur0.57 on tuesday - reflecting france's cac 40 index's dip of 1.35% towards eur7,220.92, signalling an overall downward market trend.

orege's recent decline follows a period of underperformance

with shares closing at eur0.63 on thursday - 22.93% below its 52-week high of eur0.82. this suggests a bearish outlook on orege.

decreased demand for orege's shares

with orege's share price decreasing, its trading volume correspondingly dropped significantly below its average volume of 225,080; this indicates decreased demand for its shares.

falling share prices and its reflection on the financial health

orege's falling share prices should not be taken as the sole indicator of its financial health; over the past year it declared a loss, with ttm earnings per share (eps) falling to eur-0.12. such a negative figure reflects more spending than earnings - making the company less desirable among confident investors.

investor caution amid broader stock market instability

as investors remain wary of orege and its performance amid broader stock market instability, investors are exercising caution. orege, an eren groupe sa subsidiary, may need to review its strategic activity and increase shareholder trust in order to revitalize future stock performance.

more news about orege (orege.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com